MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study DOI Creative Commons

Mariateresa Zicarelli,

Marta Greco, Stefanos Roumeliotis

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(2), P. 322 - 322

Published: Feb. 12, 2025

Background and Objectives: Sarcopenia is exceedingly frequent in end-stage kidney disease (ESKD) patients on dialysis, including those undergoing peritoneal dialysis (PD), of multifactorial origin. MOTS-c a mitochondrial-derived peptide that promotes muscle growth whose levels are unbalanced ESKD. In this study, we evaluated balance its relationship with sarcopenia risk an ESKD-PD cohort. Materials Methods: was measured serum, urine, dialysate samples 32 chronic PD patients. Patients were thus screened for by the SARC-F tool, anthropometric measurements, physical performance tests. Results: very high (SARC-F ≥ 2) had significantly lower serum (sMOTS-c) higher (dMOTS-c) levels, suggesting increased clearance substance (d/s MOTS-c). sMOTS-c directly correlated tests, while opposite found dMOTS-c d/sMOTS-c. ROC analyses demonstrated diagnostic potential MOTS-c, particularly combination assessments, to identify at sarcopenia. Conclusions: Chronic may negatively affect balance, which, turn, contribute enhanced risk. Larger studies needed confirm these observations validate utility as biomarker improving stratification

Language: Английский

Novel therapeutic targets for cardiorenal syndrome DOI

Mansi Vinodkumar Trivedi,

Hemant R. Jadhav,

Anil Bhanudas Gaikwad

et al.

Drug Discovery Today, Journal Year: 2025, Volume and Issue: unknown, P. 104285 - 104285

Published: Jan. 1, 2025

Language: Английский

Citations

0
MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study DOI Creative Commons

Mariateresa Zicarelli,

Marta Greco, Stefanos Roumeliotis

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(2), P. 322 - 322

Published: Feb. 12, 2025

Background and Objectives: Sarcopenia is exceedingly frequent in end-stage kidney disease (ESKD) patients on dialysis, including those undergoing peritoneal dialysis (PD), of multifactorial origin. MOTS-c a mitochondrial-derived peptide that promotes muscle growth whose levels are unbalanced ESKD. In this study, we evaluated balance its relationship with sarcopenia risk an ESKD-PD cohort. Materials Methods: was measured serum, urine, dialysate samples 32 chronic PD patients. Patients were thus screened for by the SARC-F tool, anthropometric measurements, physical performance tests. Results: very high (SARC-F ≥ 2) had significantly lower serum (sMOTS-c) higher (dMOTS-c) levels, suggesting increased clearance substance (d/s MOTS-c). sMOTS-c directly correlated tests, while opposite found dMOTS-c d/sMOTS-c. ROC analyses demonstrated diagnostic potential MOTS-c, particularly combination assessments, to identify at sarcopenia. Conclusions: Chronic may negatively affect balance, which, turn, contribute enhanced risk. Larger studies needed confirm these observations validate utility as biomarker improving stratification

Language: Английский

Citations

0